Acrivon Therapeutics Inc

For the period ended Jun 20, 2024. Filed Apr 26, 2024.

About this filing

What shareholders are asked to vote on at a company's meeting. It is where to find what directors and top executives are paid, and who owns the most shares.

Jun 20, 2024 · Filed Apr 26, 2024

ACRV$1.61+2.5%Stored close · as of Nov 6, 2026

See the whole filing, with its images and exhibits

Contents

Availability of Certain Information

A copy of the 2023 Annual Report has been posted on the Internet along with this Proxy Statement, each of which is accessible by following the instructions in the Notice. We filed the 2023 Annual Report with the SEC on March 28, 2024. We will mail without charge, upon written request, a copy of the 2023 Annual Report, excluding exhibits. Please send a written request to Investor Relations, Acrivon Therapeutics, Inc., 480 Arsenal Way, Suite 100, Watertown, MA 02472.

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.